According to the CDC, breast cancer is the most commonly diagnosed type of cancer among American women, after certain types of skin cancer. For most, treatment includes radiation therapy, which often results in damage to healthy nearby tissue. In 2007, Focal Therapeutics, a Aliso Viejo, California firm, was established by James Stubbs, Ph.D., George Hermann, and Dr. Lebovic to “help surgeons, radiation oncologists, and other clinicians to clearly identify a surgical site through the use of an innovative tissue marker”. The company’s first product, BioZorb is a tissue marker that is sutured in place by the surgeon during a lumpectomy after tumor removal. It received 510(k) clearance from the U.S. Food and Drug Administration in February 2012 and went into initial clinical use later that year. It is currently used in the United States and New Zealand and has continued to receive recognition from physicians. There is no other product that three dimensionally marks the surgical site during a lumpectomy.
Tags :- medical-news ,
SHARE PLEASE - 2015-08-22 08:34:36